WG
SNDX icon

Winton Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Winton Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Buy
76,500
+66,200
+643% +$1.38M 0.05% 341
2026
Q1 		$241K Sell
10,300
-4,274
-29% -$92.9K 0.01% 932
2025
Q4 		$306K Sell
14,574
-7,947
-35% -$139K 0.01% 735
2025
Q3 		$346K Buy
+22,521
New +$295K 0.01% 613

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Winton Group's SNDX Position: Q2 2026 in Review

Winton Group increased its Syndax Pharmaceuticals (SNDX) stake by 643% in Q2 2026, buying an estimated $1.38M and bringing the position to 76,500 shares worth $1.67M. The position accounts for 0.05% of the portfolio, ranked #341.

Winton Group first reported a position in SNDX in Q3 2025 and has held it in 4 quarters since. 152 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Winton Group held 76,500 shares of Syndax Pharmaceuticals worth $1.67M as of Q2 2026.
  • Winton Group bought 66,200 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.38M.
  • Syndax Pharmaceuticals made up 0.05% of Winton Group's portfolio in Q2 2026, its #341 holding.
  • Winton Group first reported a position in Syndax Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 152 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.